Skip to main content


Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Fig. 1

TTP and duration of treatment in patients with best response of SD to romidepsin. PTCL subtypes and response by exploratory PET endpoint are shown on Y axis. Vertical line indicates 90 days of treatment; asterisk indicates patients that discontinued due to adverse event; and dagger sign indicates patients that discontinued due to patient decision. E-type TCL enteropathy-type T cell lymphoma, P-like TCL subcutaneous panniculitis-like T cell lymphoma

Back to article page